Decitabine Combination Therapy Pre-ASCT

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
36 patients (estimated)
Sponsors
Fred Hutchinson / University of Washington Cancer Consortium
Tags
Allogeneic Stem Cell Transplant, Chemotherapy, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
2 days ago
SparkCures ID
2118
NCT Identifier
NCT06928662

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.